Soft tissue sarcomas (STSs) are rare malignant tumors that are difficult to prognosticate using currently available instruments. Omics sciences could provide more accurate and individualized survival predictions for patients with metastatic STS. In this pilot, hypothesis-generating study, we integrated clinicopathological variables with proton nuclear magnetic resonance (1H NMR) plasma metabolomic and lipoproteomic profiles, capturing both tumor and host characteristics, to identify novel prognostic biomarkers of 2-year survival. Forty-five metastatic STS (mSTS) patients with prevalent leiomyosarcoma and liposarcoma histotypes receiving trabectedin treatment were enrolled. A score combining acetate, triglycerides low-density lipoprotein (LDL)-2, and red blood cell count was developed, and it predicts 2-year survival with optimal results in the present cohort (84.4% sensitivity, 84.6% specificity). This score is statistically significant and independent of other prognostic factors such as age, sex, tumor grading, tumor histotype, frailty status, and therapy administered. A nomogram based on these 3 biomarkers has been developed to inform the clinical use of the present findings.

Novel metabolomics-biohumoral biomarkers model for predicting survival of metastatic soft-tissue sarcomas / Vignoli, Alessia; Miolo, Gianmaria; Tenori, Leonardo; Buonadonna, Angela; Lombardi, Davide; Steffan, Agostino; Scalone, Simona; Luchinat, Claudio; Corona, Giuseppe. - In: ISCIENCE. - ISSN 2589-0042. - ELETTRONICO. - 26:(2023), pp. 107678-107678. [10.1016/j.isci.2023.107678]

Novel metabolomics-biohumoral biomarkers model for predicting survival of metastatic soft-tissue sarcomas

Vignoli, Alessia;Tenori, Leonardo;Luchinat, Claudio;
2023

Abstract

Soft tissue sarcomas (STSs) are rare malignant tumors that are difficult to prognosticate using currently available instruments. Omics sciences could provide more accurate and individualized survival predictions for patients with metastatic STS. In this pilot, hypothesis-generating study, we integrated clinicopathological variables with proton nuclear magnetic resonance (1H NMR) plasma metabolomic and lipoproteomic profiles, capturing both tumor and host characteristics, to identify novel prognostic biomarkers of 2-year survival. Forty-five metastatic STS (mSTS) patients with prevalent leiomyosarcoma and liposarcoma histotypes receiving trabectedin treatment were enrolled. A score combining acetate, triglycerides low-density lipoprotein (LDL)-2, and red blood cell count was developed, and it predicts 2-year survival with optimal results in the present cohort (84.4% sensitivity, 84.6% specificity). This score is statistically significant and independent of other prognostic factors such as age, sex, tumor grading, tumor histotype, frailty status, and therapy administered. A nomogram based on these 3 biomarkers has been developed to inform the clinical use of the present findings.
2023
26
107678
107678
Vignoli, Alessia; Miolo, Gianmaria; Tenori, Leonardo; Buonadonna, Angela; Lombardi, Davide; Steffan, Agostino; Scalone, Simona; Luchinat, Claudio; Cor...espandi
File in questo prodotto:
File Dimensione Formato  
PIIS2589004223017558.pdf

accesso aperto

Tipologia: Pdf editoriale (Version of record)
Licenza: Open Access
Dimensione 3.45 MB
Formato Adobe PDF
3.45 MB Adobe PDF

I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificatore per citare o creare un link a questa risorsa: https://hdl.handle.net/2158/1330551
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 1
  • ???jsp.display-item.citation.isi??? 1
social impact